Cell/Gene Tx channel feed
SonoThera raises $125M for non-viral gene therapy approach
5 days ago
A father built a gene therapy for his daughter. He says an FDA request is the bottleneck
6 days ago
Lilly strikes Ascidian deal worth up to $1.9B for RNA editing in kidney diseases
Last week
FDA details flexibilities for new cell and gene therapies to leverage past data
Last week
Legend Biotech shares first in vivo CAR-T data, its next act after Carvykti
Last week
Epigenetic editing shows promise against chronic hep B infections
2 weeks ago
After leaving Legend, founding scientist Frank Fan is ready to showcase his next project
3 weeks ago
Charles River CEO says it likely won’t be the last manufacturer to break away from cell and gene therapy
3 weeks ago
Exclusive: China gene editing startup YolTech raises $70M to move CRISPR therapies forward
3 weeks ago
Exclusive: Waypoint Bio raises $20M to run three CAR-T trials in China
3 weeks ago
Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout
3 weeks ago
Fetal gene therapy inches closer. Will embryo editing follow?
4 weeks ago
A Zillow-like marketplace for abandoned gene therapies goes live
Last month
Encoded's gene therapy reduced seizures in Dravet syndrome
Last month
ASGCT dispatch: In vivo CAR-T is everywhere
Last month
Regenxbio's Duchenne study succeeded. Will it be enough to convince the FDA?
Last month
After an apparent cure, a gene editing company struggles to repeat the magic
Last month
Tessera says infusion edits 85% of blood cells, pointing to off-the-shelf sickle cell fix
Last month
Flagship startup says it has solved non-viral gene therapy in monkeys, but details remain murky
Last month
European regulators greenlight first clinical test of GLP-1 gene therapy
Last month
Atara, Pierre Fabre will get another shot at FDA approval, a week after Prasad's departure
Last month
Exclusive: Startup aims to lift mRNA out of purgatory with more durable therapies
Last month
J&J axes pair of CAR-T therapies for lymphoma, citing evolving market
Last month
Lilly strikes second partnership this year for recombinase-based gene editing
Last month